Literature DB >> 17083757

ACR remission criteria and response criteria.

V K Ranganath1, D Khanna, H E Paulus.   

Abstract

As additional DMARDs have been added to the armamentarium of rheumatologists over the last 60 years, the approach to the treatment of rheumatoid arthritis has changed. Many clinical studies now are geared toward evaluating the concept of eradicating inflammation as a method to seek the elusive goal of sustained remission in RA. One of the first descriptions of remission in 'RA' was by Short et al in 1948, when he documented the natural progression of the disease. Since that time, various criteria have been developed to define RA remission utilizing clinical, radiographic, and laboratory measures. The most stringent of criteria is the American College of Rheumatology Remission Criteria, developed in 1980, which consists of clinical symptoms and signs of inflammation including fatigue, joint pain, morning stiffness, joint tenderness, joint swelling, and erythrocyte sedimentation rate (ESR). Several reports have compared ACR remission criteria to Disease Activity Score (DAS) values to identify equivalent DAS remission values, and these have been extrapolated to modified versions of the DAS, the Simple Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI). The ACR remission criteria and the response measures were not designed for use as the target or goal for the clinical management of individual RA patients in routine clinical practice. Nevertheless, rheumatologists yearn for the eradication of inflammation in all RA patients, and attaining remission may be achievable in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083757

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  11 in total

1.  Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.

Authors:  Raymond S Douglas; Angelo Tsirbas; Mark Gordon; Diana Lee; Nicole Khadavi; Helene Chokron Garneau; Robert A Goldberg; Kenneth Cahill; Peter J Dolman; Victor Elner; Steve Feldon; Mark Lucarelli; Jimmy Uddin; Michael Kazim; Terry J Smith; Dinesh Khanna
Journal:  Arch Ophthalmol       Date:  2009-09

2.  Effect of Artemisia annua extract on treating active rheumatoid arthritis: A randomized controlled trial.

Authors:  Min Yang; Ming-Yang Guo; Yong Luo; Ming-Dong Yun; Jiao Yan; Tao Liu; Chang-Hong Xiao
Journal:  Chin J Integr Med       Date:  2016-12-29       Impact factor: 1.978

3.  The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis.

Authors:  M I Danila; A O Westfall; K Raman; L Chen; R J Reynolds; L B Hughes; D K Arnett; G McGwin; A J Szalai; D M van der Heijde; D Conn; L F Callahan; L W Moreland; S L Bridges
Journal:  Genes Immun       Date:  2015-07-30       Impact factor: 2.676

4.  Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis.

Authors:  Jeffrey D Greenberg; Leslie R Harrold; Mary J Bentley; Joel Kremer; George Reed; Vibeke Strand
Journal:  Rheumatology (Oxford)       Date:  2009-04-24       Impact factor: 7.580

Review 5.  Applying science in practice: the optimization of biological therapy in rheumatoid arthritis.

Authors:  Sofia Ramiro; Pedro Machado; Jasvinder A Singh; Robert B Landewé; José António P da Silva
Journal:  Arthritis Res Ther       Date:  2010-11-04       Impact factor: 5.156

6.  Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis.

Authors:  Frank Buttgereit; Gisela Doering; Achim Schaeffler; Stephan Witte; Stanislaw Sierakowski; Erika Gromnica-Ihle; Slawomir Jeka; Klaus Krueger; Jacek Szechinski; Rieke Alten
Journal:  Ann Rheum Dis       Date:  2010-06-11       Impact factor: 19.103

7.  The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.

Authors:  Nuria C Navarro Coy; Sarah Brown; Ailsa Bosworth; Claire T Davies; Paul Emery; Colin C Everett; Catherine Fernandez; Janine C Gray; Suzanne Hartley; Claire Hulme; Anne-Maree Keenan; Christopher McCabe; Anthony Redmond; Catherine Reynolds; David Scott; Linda D Sharples; Sue Pavitt; Maya H Buch
Journal:  BMC Musculoskelet Disord       Date:  2014-12-23       Impact factor: 2.362

8.  Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.

Authors:  Iris M Markusse; Jeska K de Vries-Bouwstra; K Huub Han; Peter A H M van der Lubbe; Anne A Schouffoer; Pit J S M Kerstens; Willem F Lems; Tom W J Huizinga; Cornelia F Allaart
Journal:  Arthritis Res Ther       Date:  2014-09-25       Impact factor: 5.156

Review 9.  Goals for rheumatoid arthritis: treating to target or treating to prevent?

Authors:  Min Yang; Mingyang Guo
Journal:  Open Access Rheumatol       Date:  2012-07-09

Review 10.  Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.

Authors:  M F Bakker; J W G Jacobs; S M M Verstappen; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 27.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.